Arcturus Therapeutics Holdings, Inc. (ARCT) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Keros Therapeutics, Inc.

Innoviva, Inc.

Collegium Pharmaceutical, Inc.

Ardelyx, Inc.

NewAmsterdam Pharma Co. NV

REGENXBIO, Inc.

Arcturus Therapeutics Holdings, Inc.

Pharvaris NV

ACELYRIN, Inc.

POINT Biopharma Global, Inc.

Intercept Pharmaceuticals, Inc.

Why is Arcturus Therapeutics Holdings, Inc. ?

Poor Management Efficiency with a low ROE of 6.34%

The company has been able to generate a Return on Equity (avg) of 6.34% signifying low profitability per unit of shareholders funds

With a fall in Net Sales of -3.8%, the company declared Very Negative results in Jun 25

The company has declared negative results for the last 2 consecutive quarters
NET SALES(Q) At USD 24.51 MM has Fallen at -25.31%
PRE-TAX PROFIT(Q) At USD -5.35 MM has Fallen at -64.11%
NET PROFIT(Q) At USD -5.35 MM has Fallen at -69.04%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -56.61%, its profits have risen by 56.4%

Below par performance in long term as well as near term

Along with generating -56.61% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Arcturus Therapeutics Holdings, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Arcturus Therapeutics Holdings, Inc.

-56.61%

-0.81

98.79%

S&P 500

11.09%

0.56

19.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

57.72%

EBIT Growth (5y)

-1.23%

EBIT to Interest (avg)

-48.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.64

Tax Ratio

0.54%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

392.01%

ROE (avg)

6.34%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.48

EV to EBIT

-2.83

EV to EBITDA

-3.10

EV to Capital Employed

-36.48

EV to Sales

0.84

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-5.41%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 1.34% (YoY

-28What is not working for the Company

NET SALES(Q)

At USD 24.51 MM has Fallen at -25.31%

PRE-TAX PROFIT(Q)

At USD -5.35 MM has Fallen at -64.11%

NET PROFIT(Q)

At USD -5.35 MM has Fallen at -69.04%

DEBT-EQUITY RATIO (HY)

Highest at -97.17 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.32 times

Here's what is working for Arcturus Therapeutics Holdings, Inc.

Raw Material Cost

Fallen by 1.34% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Arcturus Therapeutics Holdings, Inc.

Net Sales

At USD 24.51 MM has Fallen at -25.31%

over average net sales of the previous four periods of USD 32.82 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -5.35 MM has Fallen at -64.11%

over average net sales of the previous four periods of USD -3.26 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -5.35 MM has Fallen at -69.04%

over average net sales of the previous four periods of USD -3.16 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -97.17 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 5.32 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio